NCT06773130View on ClinicalTrials.gov

HRS-4642 Combined with Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

March 31, 2027

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
DRUG

HRS-4642

HRS-4642 will be administrated per dose level in which the patients are assigned.

DRUG

Nimotuzumab

400mg，ivgtt，d1，qw

Trial Locations (1)

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER